MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2024


	Warrants Outstanding			Weighted Average Exercise Price			Weighted Average Remaining Contractual Term in Years
Balance at January 1, 2024		3,650,278		$	2.82			5.00
Issued		2,949,169			1.65
Exercised		(1,157,201	)		(1.98	)
Expired		—			—
Balance at June 30, 2024		5,442,246		$	2.37			4.87

Summary of Activity and Information regarding Outstanding and Exercisable Options

The following table summarizes the activity and information regarding MAIA’s outstanding and exercisable options for the six months ended June 30, 2024:


	Options Outstanding			Weighted Average Exercise Price			Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Balance at January 1, 2024		7,750,152		$	2.53			7.29
Granted		2,353,664			2.41
Exercised		(101,837	)		(1.82	)
Cancelled/forfeited		(679,531	)		(3.62	)
Balance at June 30, 2024		9,322,448		$	2.43			7.17		11,601,885
Options exercisable at June 30, 2024		6,657,826		$	2.32			6.64		9,253,514

Assumptions used in Calculating Value of Options Granted

The value of option grants is calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the six months ended June 30, 2024 and 2023:


	2024		2023
Risk-free interest rate	3.94%-4.77%		3.64%-4.23%
Expected term (in years)	5 - 6.25		5 - 6.25
Expected volatility	95%-152.5%		99.6%-101.0%
Expected dividend yield		—	—%

Summary of Stock Based Compensation Expense

Stock based compensation related to the Company’s stock plans are as follows:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,

	2024		2023		2024		2023
General and administrative	$	256,916	$	334,054	$	487,905	$	590,730
Research and development		157,032		284,878		276,008		565,723
Total stock-based compensation	$	413,948	$	618,932	$	763,913	$	1,156,453